Ranking Company Name
1 Yangzijiang Pharmaceutical Group Limited (including: Shanghai Haini Pharmaceutical Co., Ltd., Yangzijiang Pharmaceutical Group)
2 Hafen Pharmaceutical Group Co.
3Correction Pharmaceutical Group
4Shiyu Pharmaceutical Group Co., Ltd (including: Shiyu Pharmaceutical Group Zhongnuo Pharmaceutical (Shijiazhuang) Ltd, Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd, Shiyu Pharmaceutical Yinhu Pharmaceutical Co. Ltd.)
6Weigao Group Co.
7North China Pharmaceutical Group Co. Ltd., Taiji Group Mianyang Pharmaceutical Co., Ltd., Southwest Pharmaceutical Co., Ltd., Taiji Group Chongqing Tongjunge Pharmaceutical Co., Ltd., Taiji Group Chongqing Traditional Chinese Medicine No.2 Factory, Taiji Group Sichuan Taiji Pharmaceutical Co., Ltd., Taiji Group Zhejiang Dongfang Pharmaceutical Co., Ltd. and Taiji Group Sichuan Tiancheng Pharmaceutical Co.)
10Beijing Shuanghe Pharmaceutical Co. Ltd. (including: Anhui Shuanghe Pharmaceutical Co., Ltd., Beijing Wanhui Shuanghe Pharmaceutical Co., Ltd., Xi'an Jingxi Shuanghe Pharmaceutical Co., Ltd., Shanxi Jinxin Shuanghe Pharmaceutical Co., Ltd. and Beijing Shuanghe Modern Pharmaceutical Technology Co.)
11 China Resources Sanjiu Medicine Co. Qilu Pharmaceutical Co., Ltd (including: Qilu Pharmaceutical (Hainan) Co., Ltd, Qilu Tianhe Huishi Pharmaceutical Co., Ltd, Qilu Anti Pharmaceutical Co., Ltd)
14 Zhejiang Medicine Co. >16Sichuan Kelun Pharmaceutical Co., Ltd (including: Hunan Kelun Pharmaceutical Co., Ltd, Jiangxi Kelun Pharmaceutical Co., Ltd, Hunan Zhongnan Kelun Pharmaceutical Co., Ltd, Heilongjiang Kelun Pharmaceutical Co., Ltd, Shandong Kelun Pharmaceutical Co., Ltd, Hubei Tuopeng Pharmaceutical Co., Ltd, Kunming Nanyang Pharmaceutical Co., Ltd, Liaoning Minkang Pharmaceutical Co., Ltd, Sichuan Pearl Pharmaceutical Co. Ltd., Heilongjiang Kelun Pharmaceutical Packaging Co., Ltd., Sichuan Kelun Pharmaceutical Packaging Co., Ltd., Jilin Kelun Cornell Pharmaceutical Co., Ltd., Sichuan Kelun Pharmaceutical Co., Ltd. Guang'an Branch, Sichuan Kelun Pharmaceutical Co., Ltd. Renshou Branch)
17Zhejiang Hai Zheng Pharmaceutical Co.
18Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Shanghai Chaohui Pharmaceutical Co., Ltd., Chongqing Kailin Pharmaceutical Co., Ltd., Guilin Nanzhu Pharmaceutical Co., Ltd. and Shanghai Clone Bio-High-Tech Co.)
19 Ruiyang Pharmaceutical Co.,Ltd.
20Fuuren Pharmaceutical Group Co. Ltd., Henan Huaiqingtang Pharmaceutical Co., Ltd. and Henan Tongyuan Pharmaceutical Co.)
21 Shandong Pharmaceutical Glass Co.,Ltd.
22 Pfizer Pharmaceutical Co.Ltd.
23 Zhejiang Xinhecheng Co.Ltd.
24 Lunan Pharmaceutical Group Co., Ltd. (Including: Lunan Bett Pharmaceutical Co.,Ltd. Ltd.)
25 Sanofi Aventis (Hangzhou) Pharmaceutical Co.
26 Renhe (Group) Development Co.
27 Lizhu Pharmaceutical Group Co.
27 Lizhu Pharmaceutical Group Co.
27 Lizhu Pharmaceutical Group Co.
27 Lizhu Pharmaceutical Group Co.
27 Lizhu Pharmaceutical Group Co.
27 Lizhu Pharmaceutical Group Co.
27 Lzhu Pharmaceutical Group Co. Ltd., Lizhu Group Limin Pharmaceutical Factory, Lizhu Group Xinbeijiang Pharmaceutical Company Limited, Lizhu Group Zhuhai Free Trade Zone Lida Pharmaceutical Company Limited)
28Shandong Xinhua Pharmaceutical Group Limited Company
29Hangzhou Merck Sharp & Dohme Pharmaceutical Company Limited
30Beijing Novartis Pharmaceutical Company Limited
31Henan Tianfang Pharmaceutical Co. Ltd.
32 China Resources Dong'a Gum Co.
33 Zhejiang Shenghua Baike Biological Co.
34 Xianxin Pharmaceutical Co.
34 Xianxing Pharmaceutical Co. Ltd.
36 Henan Province Wanshi Pharmaceutical Co.
37 Lijun Pharmaceuticals (including: Shijiazhuang Four Pharmaceuticals Co.
38 Shandong Lubao Pharmaceuticals Co.
39 Jiangzhong Pharmaceuticals Co.
40 Jiangsu Jichuan Ltd.
41Shandong Luoxin Pharmaceutical Co.
42Jiangsu Kangyuan Group Co.
42Jiangsu Kangyuan Group Co.
42Jiangsu Kangyuan Group Co.
42Jiangsu Kangyuan Group Co.
42Jiangsu Kangyuan Group Co.
42Jiangsu Kangyuan Group Co.
42Jiangsu Kangyuan Group Co.
42Jiangsu Kangyuan Group Co.
42Jiangsu Kangyuan Pharmaceutical Co. Ltd.
44 Guangzhou Baiyunshan Pharmaceutical Company Limited (including: Guangzhou Baiyunshan Hutchison Whampoa Chinese Medicine Company Limited, Guangzhou Baiyunshan Tianxin Pharmaceutical Company Limited, Guangzhou Baiyunshan Mingxing Pharmaceutical Company Limited, Guangzhou Baiyunshan Guanghua Pharmaceutical Company Limited, Guangzhou Baitiao Qiaoguang Medical Supplies Company Limited)
45 Shandong Zibo Shanchuan Medical Equipment Co. Ltd.
46Jiangsu Zhengda Tianqing Pharmaceutical Co.
47Shijiazhuang Ealing Pharmaceutical Co.
48Meiro Pharmaceutical Co.
49Chengdu Dior Group
50Anhui Fengyuan Pharmaceutical Co.
51Zhejiang Jianfeng Pharmaceutical Co.
52Shandong Ltd.
53 Guangzhou Wanglaoji Pharmaceutical Co.
54 Wuhan Renfu Pharmaceutical Group Co.
55 Zhejiang Kangenbe Pharmaceutical Co.
56 Shandong Xianhe Pharmaceutical Co.
57 Shandong Lubai Chenxin Pharmaceutical Co.
58 Omron (Dalian) Co. Ltd.
59 Zhejiang Xianju Pharmaceutical Co.
60 Jiangsu Osaikang Pharmaceutical Co.
61 Donggang Industry & Trade Group Co.
62 Tian Sheng Pharmaceutical Group Co.
63 Heilongjiang Jenbaojiao Pharmaceutical Co.
64 Jiangsu Suzhong Pharmaceutical Group Co. Ltd.
65 Hualan Bioengineering Co. (including: Hualan Biovaccine Co.
66 Hangzhou Zhongmei Huadong Pharmaceutical Co.
67 Beijing Tongrentang Science and Technology Development Co.
68 Shanxi Weichida Pharmaceutical Co.
69 Shanghai Hyundai Pharmaceutical Co.
69 Shanghai Hyundai Pharmaceutical Co.
(including: Ltd.)
70Yuekang Pharmaceutical Group Co.
71Guilin Sanguine Group Co.
71Guilin Sanguine Pharmaceutical Co.
72Ningxia Qiyuan Pharmaceutical Co.
72Ningxia Qiyuan Pharmaceutical Co. /Ltd.
73Jiuzhitang Co.
74Shanghai Xinya Pharmaceutical Co.
75Jiangsu Enhua Pharmaceutical Co.
76Heilongjiang Sunflower Pharmaceutical Co.
77Anqiu Lu'an Pharmaceutical Co.
78Hezel Ruiying Pharmaceutical Group Co. 79Beijing Fresenius Kabi Pharmaceutical Co.
80Guizhou Yibai Pharmaceutical Co., Ltd (including: Guilin Yibai Lijiang Pharmaceutical Co., Ltd, Hainan Chang'an International Pharmaceutical Co., Ltd)
81Shenzhen Zhijun Pharmaceutical Co.
82Disha Pharmaceutical Group Co.
83Jiangsu Soviet Union Ring Pharmaceutical Group Co.
84Jiangsu Yabang Pharmaceutical Group Co., Ltd (including: Jiangsu Yabang Apson Pharmaceutical Co., Ltd, Jiangsu Yabang Shengyuan Pharmaceutical Co., Ltd, Jiangsu Yabang Qiangsheng Pharmaceutical Co., Ltd)
85Hengdian Group Kangyu Pharmaceutical Co.
86Zhengda Youthful Bao Pharmaceutical Co.
87Lanzhou Biological Products Research Institute
88Shandong Tianli Pharmaceutical Co.
89Fujian Fuzhang Pharmaceutical Co.
90Sichuan Shuzhong Pharmaceutical Co.
91Beijing Tongrentang Health Pharmaceutical Co.
92Anstellas Pharma (China) Co.
93Shanghai Xinxiang Pharmaceutical Co.
94 Ltd.
95Zhejiang Huahai Pharmaceutical Co.
96Liaoning Nuokang Biopharmaceutical Co.
97Beijing Tide Pharmaceutical Co.
98Zhejiang Hailisheng Pharmaceutical Co.
99Shandong Xinhua Medical Instrument Group
100Shanghai Baxter Medical Supplies Co. Ltd.
The following industry trends:
In the recent year, the domestic pharmaceutical industry has frequently appeared giant consolidation, Shanghai Pharmaceutical Group Corporation (hereinafter referred to as "Shanghai Pharmaceutical Group") and Shanghai Industrial (Group) Co. "(hereinafter referred to as "Shanghai Pharmaceuticals Group") and Shanghai Industrial (Group) Co. April 12 this year, the successful reorganization of the Shanghai Institute of Pharmaceutical Industry (hereinafter referred to as "Institute of Medicine") to establish a new Sinopharm; just before this 10 days, China Resources Group and the Beijing Municipal People's Government formally signed the "*** with the development of the pharmaceutical industry and the microelectronics industry of the strategic cooperation framework agreement", China Resources formally will be the northern medicine into the arms of the establishment of the new China Resources! The establishment of the new China Resources. Thus, with the completion of the domestic pharmaceutical mergers and reorganization of the three giants, since 2009, the pharmaceutical industry mergers and acquisitions since 2000, the highest amount of transactions since the peak of the competitive pattern of the pharmaceutical market has obviously changed, China's pharmaceutical industry formally stepped into the era of the Three Kingdoms. The new Sinopharm, the new China Resources, the new on the drug 3 seat row, re-arrangement of the industry after the big boys surfaced, the recent national requirements in the domestic formation of several pharmaceutical leader group of vision has been initially realized.
New Sinopharm
China's pharmaceutical industry is still the uncontested leader of the new Sinopharm Group. on April 12, the whole of the Institute of Medical Technology into the Sinopharm Group, becoming a wholly-owned subsidiary of the. SASAC to fulfill the responsibilities of the funder of enterprises from 127 adjusted to 126. The integration of the whole of the Institute of Medicine into Sinopharm is of great significance to Sinopharm. Although Sinopharm as the absolute leader of the domestic pharmaceutical industry, but in its profit composition, 80% from Sinopharm Holdings on behalf of the pharmaceutical companies, even if the reorganization of the biological products of Sinopharm Group has a sustained high profit contribution, it is always difficult to cover up Sinopharm in the pharmaceutical industry on the obvious shortcomings. The more pressing problem is that the first integrated out of the mountain of the new drug is firmly entrenched in East China, another giant of the central enterprises, China Resources Group has never stopped acquiring ambitions and footsteps, in the new health care reform grass-roots sinking under the impetus of the regional leaders around the world are not willing to show weakness, have allied against. Under the "internal and external problems", the Institute of Medicine in the national medicine, has been a trump card that must be taken.
In China's pharmaceutical research field, the Institute of Medical Technology has been a proud existence - as the central enterprises in the sequence of the only pharmaceutical industry research institutes, the Institute of Medical Technology has been subordinate to the Central Enterprise Work Committee, the State Council State-owned Assets Supervision and Administration Commission. More than 30 listed companies in the pharmaceutical sector of the Shanghai and Shenzhen stock markets to its output of scientific research as the main product, the target revenue of 1.5 billion yuan in 2010, the main business is the research and development of innovative drugs, pharmaceutical production, sales, R & D strength of the country's leading. Although its annual revenue is less than 1 billion yuan, but its strong scientific research power, become the State Pharmaceutical Group's industrial engine and fission machine. Two industrial enterprises under the Institute of Medical Technology, Modern Pharmaceuticals and Shanghai Modern Pharmaceutical Preparations Engineering Research Center Co., Ltd. have performed very well, and it is even difficult to value the economic and social benefits.
April 22, China Pharmaceutical Group and Shanxi Wichita Pharmaceutical (hereinafter referred to as "Wichita") signed an agreement in Datong, Shanxi Province, Sinopharm officially began the reorganization of Wichita. Sinopharm is committed to realizing a controlling stake in Wichita through equity acquisition and capital increase. This is the first step for Sinopharm to launch its own merger and acquisition in the field of pharmaceutical industry, which is of great significance and can accelerate the process of Sinopharm's industrialization. At the same time, after the merger and acquisition of Wichita, Sinopharm will definitely open a breakthrough in Shanxi and introduce other businesses into this region. Wichita is the main producer of medical intermediate 7-ACA in China, and the direct downstream product of this intermediate is ceftriaxone sodium. China is a big country in the use of anti-infective drugs, the national anti-infective drugs with an average annual rate of about 17% of the rapid growth, in 2009 the national anti-infective drugs market size has exceeded 40 billion yuan. Ceftriaxone sodium has been the top selling antibiotic, and in 2008, the China Pharmaceutical Society conducted statistics on 22 hospitals nationwide, and the amount of ceftriaxone sodium medication reached 269.78 million yuan, far exceeding that of other drugs. Shiyao Group and Fuzhou Antibiotics Group are the big producers of 7-ACA, with an annual production capacity of about 1,600 tons. Wichita ranks third with about 1,000 tons, and companies such as Healthyuan have an annual production capacity of less than 800 tons. In the restructuring agreement, Sinopharm said it will further expand Vichida's production capacity to achieve a production scale of 1,200 tons of 7-ACA and 300 tons of clavulanic acid. It also plans to realize sales revenue of more than 3 billion yuan from Vichida by 2015.
As a platform for SASAC to integrate pharmaceutical central enterprises, Sinopharm had already pocketed Zhongsheng Group on Sept. 16, 2009, before it took down MEDIC and VICIDA. With the exclusive monopoly of the vaccine business and blood products business, Zhongsheng Group into Sinopharm's huge body of diamonds, Sinopharm has absolutely important meaning. Zhongsheng Group makes up for the lack of blood and vaccine business of Sinopharm. This move in the health care reform nearly trillion large project, and the State-owned Assets Supervision and Administration Commission will be Sinopharm Group into a trade, science and industry integrated operation of large-scale pharmaceutical group's long-term strategy coincides with. Sinopharm has become Sinopharm's eighth business segment -- previously Sinopharm was China's largest supplier of vaccines and blood products, mainly engaged in the manufacture and sale of vaccines, blood products and diagnostic reagents for the three categories of biological agents, 90 percent of China's planned vaccines from Sinopharm, which had revenues of 4.9 billion yuan in 2008.
At present, according to the vision of Song Zhiping, chairman of Sinopharm, by the end of 2010, Sinopharm's sales rankings should be squeezed into the top 40, and enter the top 30 in the central government's proposal of "30-50 internationally competitive enterprises". 2009, Sinopharm realized operating income of 65 billion yuan, and profit of 3.63 billion yuan, ranking first in the pharmaceutical industry, and second in the pharmaceutical industry. In 2009, Sinopharm achieved operating revenue of 65 billion yuan and profit of 3.63 billion yuan, ranking the first in the pharmaceutical industry in China and the 50th and 38th among 129 centralized enterprises. This year and next year, Sinopharm's sales revenue targets are set at 80 billion and 100 billion yuan respectively. Sinopharm's long-term goal is to enter the world's top 500 companies in 2015. And according to Sinopharm's forecast, the entry threshold for the world's top 500 by then will be around 160 billion yuan in terms of sales revenue.
New China Resources
Chinese Resources Pharmaceutical Group is another card in the SASAC's "building a centralized pharmaceutical platform". China Resources in the reorganization of central enterprises Huayuan Group, Sanjiu Group pharmaceutical resources, based on the growth of large-scale pharmaceutical manufacturing and distribution enterprises. China Resources Pharmaceutical annual turnover of more than 27 billion yuan, with Beijing Pharmaceuticals, Sanjiu Pharmaceuticals, China Resources Dong'a Gum and other well-known pharmaceutical companies, directly or indirectly holding Sanjiu Pharmaceuticals, Dong'a Gum, Shuanghe Pharmaceuticals, Wandong Medical and a number of listed companies. The pharmaceutical industry, together with consumer goods, electricity and real estate, is listed as the first-tier profit center of China Resources Group. China Resources has occupied the pharmaceutical sector in Shanghai, Beijing and Shenzhen three major markets, the regional layout is relatively well formed. In the health care reform last year, the introduction of the basic directory of drugs favorable, in the OTC and traditional Chinese medicine pharmaceuticals with brand advantages of Sanjiu Medicine, no doubt, and injected new vitality to China Resources. China Resources and North Drug has been in Beijing on April 2, 2010 afternoon in Beijing and the Beijing Municipal People's Government formally signed the "on the *** with the development of the pharmaceutical industry and microelectronics industry strategic cooperation framework agreement", China Resources to increase its stake in the North Drug shares may be locked in between 5% to 10%. The signing of the strategic agreement, so that China Resources Group successfully completed the rankings three into two change.
The CR reorganization of the North Drug is significant. 2006 December, China Resources 2 billion yuan in cash acquisition of Huayuan 50% of the shares of the North Drug, became the largest shareholder of the North Drug Group, in fact, China Resources has not been involved in the management of the North Drug Group, a few years its desire to further increase its holdings have not been the Beijing Municipal Government to make clear its position. At the same time, with the reorganization of Sinopharm Group, Zhongsheng Group, Medical Engineering Institute announced the completion of China Resources feel more and more pressure, such as failing to seize the North Drug, will be the rivals left behind. At the same time, the State-owned Assets Supervision and Administration Commission re-established Sinopharm as a centralized pharmaceutical platform, China Resources is very much under pressure, and hope that through this integration, its China Resources Pharmaceutical Group of pharmaceutical assets and the North Pharmaceutical Group merger, and China Resources will likely to North Pharmaceutical Group as the basis for the creation of the platform of the new China Resources Pharmaceutical Group, to regain its position in the centralized pharmaceutical sector. After the reorganization of the North Drug, China Resources control of pharmaceutical assets will include the North Drug, China Resources Sanjiu, Dong'ajiao, covering traditional Chinese medicine, health care products, pharmaceutical distribution and medical devices. Not only can make China Resources to the North Drug Group as the basis for building a new China Resources Pharmaceutical Group platform, but also can form "on the North Drug", "under the Sanjiu" pattern of medicine, the overall size of the drug also beyond the new on the second place in the country. North Drug 2009 sales revenue of 26.9 billion yuan, ranked third in China's pharmaceutical companies. Take the North Drug, China Resources Pharmaceutical 2009 revenue can increase to 33.7 billion yuan, more than the new drug, ranked second in size in China.
New ShangPharma
The new ShangPharma Group has fallen to the third in the industry, but the integration of the strength of the action began a long time ago. 2009 October, Shanghai Pharmaceuticals, a subsidiary of ShangPharma Group, through the absorption of the merger, the issuance of shares and purchase of assets, the integration of the pharmaceutical assets of SIIC and ShangPharma Group, a new ShangPharma surfaced as a pharmaceutical industry resource integration platform under the state-owned enterprises of Shanghai. 2010, the new ShangPharma will be the largest pharmaceutical company in China. At the beginning of 2010, the new ShangPharma also acquired four foreign pharmaceutical enterprises, and signed acquisition framework agreements with Guangzhou Zhongshan Pharmaceutical Company Limited, Shandong Shanglian Biochemical Pharmaceutical Company Limited and Changzhou Yabang Pharmaceutical Company Limited.
In 2009, the total assets of the new drug jumped from 8 billion yuan to 22.3 billion yuan, sales revenue jumped from 23 billion yuan to 30 billion yuan, and realized a net profit of 880 million yuan, becoming the second largest pharmaceutical group in China after Sinopharm, which has been left behind by China Resources. Although it does not belong to the sequence of central enterprises, but after the reorganization of the new ShangPharma Group's pharmaceutical commercial sales scale has been ranked first in East China. ShangPharma's plan is to reach 50 billion yuan in revenue in 2012, with more than 35 varieties exceeding 100 million yuan in 2013 and 80 billion yuan in revenue in 2015